{
  "conversation_id": "b514664201ad62fb2374e0e2af3aa32722150c70076ba619e929ea31ca15af0d",
  "chat_history": "{\n  \"messages\": [\n    {\n      \"metadata\": {},\n      \"content_type\": \"message\",\n      \"role\": \"user\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"Given the KRAS p.G12C mutation in patient_4, summarize current treatment options including KRAS inhibitors, chemo-immunotherapy, and emerging trial drugs. Include efficacy, risk profile, and how this may affect prognosis\"\n        }\n      ]\n    },\n    {\n      \"ai_model_id\": \"gpt-5-nano\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-CAwmtmXIhPQoOmmTTyNPaUuXC8xSN\",\n        \"created\": 1756725295,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 915,\n          \"completion_tokens\": 2592\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"Orchestrator\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"Plan and participants for your question\\n- Goal: Provide a comprehensive, up-to-date summary of treatment options for KRAS p.G12C-mutant cancer (with emphasis on NSCLC is most common), covering:\\n  - Approved KRAS G12C inhibitors\\n  - Chemo-immunotherapy options\\n  - Emerging trial drugs and ongoing trials\\n  - Efficacy data, risk/toxicity, and potential impact on prognosis\\n- Plan to achieve this plan (order of participants):\\n  1) PatientHistory: Retrieve patient timeline and context for patient_4 (to tailor interpretation to disease course and prior therapies).\\n  2) PatientStatus: Confirm current status: age, primary site, histology, stage, biomarkers (PD-L1, TMB if available), prior treatments, ECOG/Karnofsky score.\\n  3) ClinicalGuidelines: Provide treatment recommendations based on patient status.\\n  4) MedicalResearch: Gather high-level info on emerging KRAS G12C inhibitors and related targets in development.\\n  5) ClinicalTrials: Compile active or soon-to-open trials relevant to KRAS G12C NSCLC (or other KRAS G12C cancers if applicable) and their design.\\n  6) ReportCreation (optional): Create a board-ready summary document with patient timeline, clinical summary, history, cancer type, imaging/pathology highlights, planned plan, and trial options.\\n- Important: After each agent completes their task, they should return the answer with the line: \\\"back to you: Orchestrator\\\".\\n\\nUser input needed to proceed\\n- *User*, please confirm that you\u2019d like us to proceed with this agent-based plan to assemble a comprehensive summary. If you confirm, I will begin by pulling the patient history for patient_4 and then move through the sequence above. If there are any specifics you want emphasized (e.g., focus on first-line options, or emphasis on trial data post-2023), please tell me now.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    }\n  ]\n}",
  "patient_id": null,
  "patient_data": [],
  "display_blob_urls": [],
  "display_clinical_trials": [],
  "output_data": [],
  "healthcare_agents": {}
}